Sign up Australia
Proactive Investors - Run By Investors For Investors

Bod Australia secures supply deal for medicinal cannabis extracts

Leading pharmaceutical company Biopharma will develop a wafer style delivery method.
Cannabis plant
The shares surged 46% on Thursday to a 12 month high of $0.63

Bod Australia Ltd (ASX:BDA) will supply a range of medicinal cannabis extracts to leading pharmaceutical company iX Biopharma (SGX:42C).

The company, which develops and distributes natural, evidence-based cosmetics and natural medicines, has signed an exclusive manufacturing and commercialisation agreement.

Cannabis wafer product

Biopharma will use the extracts, which include oils and raw materials, to develop and commercialise a cannabis wafer product utilising its patented WaferiXTM delivery method.

The product will then be used in Bod’s Phase I clinical trials.

Biopharma’s WaferiXTM technology consists of a small wafer, formulated using a proprietary freeze-drying process.

Rapid absorption of compounds

The wafer, which is intended to be placed under the consumer’s tongue, dissolves within one minute, releasing contained active compounds for rapid absorption.

Administering the wafer is tolerable with no after-taste, leaving behind no residue or grittiness under the tongue preventing the urge for recipients to swallow.

The wafer style drug delivery method will be manufactured through Biopharma’s wholly-owned Australian subsidiary, iX Syrinx Pty Ltd.

Manufacturing will be in Melbourne

This will take place in a Therapeutic Goods Administration and Good Manufacturing Practice approved pharmaceutical manufacturing facility in Melbourne, Victoria.

Bod expects this will expedite the commencement of clinical trials and defray any import risks.

The company is investigating further ways to advance the clinical trial design to reduce time to market and save costs.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full BDA profile View Profile

Bod Australia Ltd Timeline

Related Articles

scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use